1. Medtech Insight
  2. >>Business

Myriad To Enter Neuroscience Market With $225m Assurex Acquisition

In its bid to develop more targeted diagnostics and build future partnerships with pharma companies, Myriad has signed a $225m deal, plus milestones, to acquire Assurex Health.

Myriad Genetics Inc. has signed a definitive agreement to acquire Assurex Health Inc. for $225m upfront to move into the neuroscience personalized medicine market. The company says it will pay out an additional $185m based on performance-based milestones. If all goes according to plan, the deal is expected to close in the first quarter of 2017.

With the deal, Myriad will gain Assurex's GeneSight, a laboratory-developed genomic test that analyzes the pharmacokinetic and pharmacodynamics effects of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Panel: FDA’s Home Healthcare Initiative Holds Promise, But Challenges Remain

 
• By Elizabeth Orr

During a recent FDLI panel, experts discussed the FDA's Home Healthcare initiative, highlighting its potential benefits and challenges. Key issues include usability testing, reimbursement, labeling for home use, and the need for innovation while ensuring patient safety.

Execs On The Move: 26-30 May 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 
• By Amanda Maxwell

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.